Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) insider Harpreet Dhaliwal sold 17,000 shares of the stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $67.83, for a total value of $1,153,110.00. Following the completion of the sale, the insider owned 68,085 shares in the company, valued at approximately $4,618,205.55. The trade was a 19.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Vaxcyte Trading Down 2.0%
Shares of PCVX stock traded down $1.32 on Friday, reaching $63.37. 623,298 shares of the company’s stock were exchanged, compared to its average volume of 2,025,302. The company’s fifty day simple moving average is $62.24 and its 200 day simple moving average is $57.65. Vaxcyte, Inc. has a 52 week low of $42.40 and a 52 week high of $90.75. The company has a current ratio of 4.56, a quick ratio of 4.56 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $10.03 billion, a PE ratio of -7.86 and a beta of 1.31.
Vaxcyte (NASDAQ:PCVX – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($1.99) EPS for the quarter, beating the consensus estimate of ($2.11) by $0.12. During the same period in the prior year, the company posted ($1.56) earnings per share. As a group, analysts forecast that Vaxcyte, Inc. will post -7.51 EPS for the current year.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $120.00 price objective on shares of Vaxcyte in a research report on Monday, October 12th. Needham & Company LLC lifted their price target on shares of Vaxcyte from $110.00 to $122.00 and gave the company a “buy” rating in a research note on Monday, October 5th. Bank of America lowered their price target on Vaxcyte from $133.00 to $130.00 and set a “buy” rating for the company in a report on Monday, September 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Friday, October 2nd. Finally, Zacks Research upgraded Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $110.50.
Get Our Latest Analysis on PCVX
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the stock. FORA Capital LLC purchased a new position in Vaxcyte in the third quarter valued at about $246,000. Pathstone Holdings LLC raised its holdings in Vaxcyte by 61.2% in the third quarter. Pathstone Holdings LLC now owns 38,482 shares of the company’s stock worth $2,400,000 after purchasing an additional 14,606 shares in the last quarter. Marshall Wace LLP bought a new position in Vaxcyte in the third quarter worth about $18,999,000. Meeder Advisory Services Inc. bought a new position in Vaxcyte in the third quarter worth about $441,000. Finally, First Trust Advisors LP purchased a new stake in shares of Vaxcyte during the third quarter valued at about $243,000. 96.78% of the stock is owned by institutional investors.
Vaxcyte Company Profile
Vaxcyte, Inc. is a clinical-stage biotechnology company developing vaccines to prevent bacterial infectious diseases. Its research focuses on conjugate vaccines, which link bacterial sugars to carrier proteins to help generate an immune response. The company’s pipeline includes VAX-24 and VAX-31, investigational pneumococcal vaccines designed to protect against a broad range of strains, as well as VAX-A1, a candidate targeting Group A Streptococcus. Vaxcyte has no approved commercial vaccines; its programs remain under development.
Further Reading
- Five stocks we like better than Vaxcyte
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.
